ClinicalTrials.gg
RecruitingNCT06791538Updated Jun 8, 2025

Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer

An interventional study of Robotic Gastrectomy and Laparoscopic Gastrectomy in Gastric Cancer, Gastroesophageal Junction Cancer, sponsored by Southwest Hospital, China. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-08.

Sponsored by Southwest Hospital, China · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
740
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This [Study Type: Clinical Trial] aims to [Primary Objective: evaluate the long-term efficacy and safety of robotic gastrectomy for locally advanced gastric cancer] in [Participant Population: patients with locally advanced gastric cancer, aged >18 years and \<75 years]. The primary questions it seeks to answer are:

Is the 3-year disease-free survival rate of robotic gastrectomy non-inferior to that of laparoscopic gastrectomy? Is the perioperative safety of robotic gastrectomy superior to that of laparoscopic gastrectomy? Researchers will compare [Intervention Groups: Robotic Gastrectomy vs. Laparoscopic Gastrectomy] to determine whether [robotic surgery offers advantages in long-term efficacy and perioperative safety].

Participants will:

Sign an informed consent form and be randomly assigned to either the robotic surgery group or the laparoscopic surgery group.

Undergo the assigned surgical procedure and receive regular follow-up visits (at 30 days, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 2 years, 2.5 years, and 3 years postoperatively).

Complete physical examinations, blood tests (including complete blood count, biochemical markers, and tumor markers), and imaging studies (such as abdominal CT, upper gastrointestinal endoscopy, and chest X-ray) during the follow-up period.

02

Conditions studied

  • Gastric Cancer, Gastroesophageal Junction Cancer

Browse trials for

Keywords

  • Robotic Gastrectomy
  • Laparoscopic Gastrectomy
03

In context

Stomach Neoplasms

3,399 studies on the registry are indexed under Stomach Neoplasms; 992 are open to participants now.

This study's planned enrollment of 740 is above the median of 66 across 2,499 interventional studies indexed under Stomach Neoplasms.

Browse Stomach Neoplasms studies →

Lead sponsor

Southwest Hospital, China is the lead sponsor of 87 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 18 years and \< 75 years.
  2. Primary gastric lesion confirmed as gastric adenocarcinoma (including papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, poorly differentiated adenocarcinoma, etc.) via endoscopic .
  3. Preoperative clinical staging as locally advanced gastric cancer (cT2-4a, N0-3, M0) according to the 8th edition of the AJCC TNM staging system.
  4. No distant on preoperative examination, and no direct invasion of the pancreas, spleen, or other adjacent organs.
  5. Preoperative performance status score of 0 or 1.
  6. Preoperative ASA () physical status score of I-III.
  7. Consent to participate in the study and signing of the form.

Exclusion criteria

Exclusion Criteria:

  1. Previous history of gastric surgery, including submucosal resection and/or endoscopic mucosal resection.
  2. History of upper abdominal surgery (excluding laparoscopic cholecystectomy).
  3. Preoperative imaging shows regional lymph nodes with confluent enlargement (maximum diameter ≥3cm).
  4. Patient underwent emergency surgery due to gastric tumor bleeding or perforation.
  5. History of other malignancies, or presence of other malignant tumors detected during preoperative examination.
  6. Patient has a history of malignant tumor, or other malignant tumors were found during preoperative examination
  7. ASA () score >3.
  8. Severe psychiatric disorders.
  9. History of unstable angina or myocardial infarction within the past 6 months.
  10. History of cerebral infarction or cerebral hemorrhage within the past 6 months.
  11. Severe pulmonary disease with \< 50%.
  12. Systemic therapy within 1 month prior to the study.
  13. Need for concurrent surgery for other diseases.
  14. Pregnant or breastfeeding women.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
740 participants (estimated)

Study arms

  • Experimental
    Robotic Gastrectomy

    Procedure: Robotic Gastrectomy

  • Active comparator
    Laparoscopic Gastrectomy

    Procedure: Laparoscopic Gastrectomy

Interventions

  • ProcedureRobotic Gastrectomy

    The intervention measures for robotic gastrectomy include: Preoperative Preparation: Comprehensive preoperative examinations, including imaging studies, laboratory tests, and tumor marker assessments, to confirm the diagnosis and staging. Surgical Procedure: Utilizing the da Vinci Surgical System, which provides a high-definition 3D view and flexible robotic arms for enhanced surgical precision. Lymphadenectomy: Systematic D2 lymph node dissection according to oncological standards to ensure thorough removal of regional lymph nodes. Gastrectomy and Reconstruction: Performing subtotal or total gastrectomy based on tumor location and extent, with intracorporeal reconstruction assisted by the robotic system. Postoperative Management: Close monitoring of vital signs, pain management, and early mobilization to facilitate recovery, along with prevention and management of postoperative complications.

  • ProcedureLaparoscopic Gastrectomy

    Preoperative Preparation: Confirm diagnosis and staging through imaging and laboratory tests. Surgical Procedure: Use standard laparoscopic instruments and 2D HD camera. Lymphadenectomy: Perform systematic D2 lymph node dissection. Gastrectomy and Reconstruction: Conduct subtotal or total gastrectomy and intracorporeal reconstruction. Postoperative Management: Monitor vital signs, manage pain, and promote early mobilization.

06

What researchers measure

Primary outcomes

  1. 3-year disease-free survival rate

    Time frame: 3 years

Secondary outcomes

  1. Overall postoperative complication rate

    Time frame: 3 years

  2. Intraoperative complication rate

    Time frame: 3 years

  3. Overall postoperative complication rate of Clavien-Dindo Grade II or higher

    Time frame: 3 years

  4. 3-year OS rate

    Time frame: 3 years

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06791538
Lead sponsor
Southwest Hospital, China
Responsible party
Yan Shi (Chief Physician, Southwest Hospital, China) — Principal investigator
First posted
Jan 24, 2025
Start date
Feb 1, 2025
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Jun 8, 2025

Study contacts

Yan Shi
Contact
shiyandoctor@sina.com
13752909448

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion